OUR LEADERSHIP TEAM, BOARD MEMBERS AND ADVISORS ARE CANCER IMMUNOLOGISTS, DRUG DEVELOPERS AND COMPANY BUILDERS WITH EXTENSIVE INDUSTRY EXPERIENCE. AS A TEAM, WE ARE LEVERAGING OUR DIVERSE EXPERTISE AND PASSION FOR INNOVATION TO BUILD A SUSTAINABLE COMPANY AND FIND CURES FOR CANCER PATIENTS.


BOARD OF DIRECTORS

Ansbert Gadicke, MD | MPM Capital, TCR2 Chairman of the Board

Dr. Gadicke is co-founder and Managing Director of MPM and Managing Director of the Oncology Impact Fund. Dr. Gadicke led the company-building effort of several of MPM’s most successful investments including Biomarin (BMRN), Idenix (acquired by Merck:MRK), Pharmasset (acquired by Gilead:GILD) and Radius (RDUS) - companies that are helping thousands of patients live longer and vastly improved lives. Sovaldi, developed by Pharmasset, is a cure for Hepatitis C and experienced the most successful product launch in the pharmaceutical industry. Prior to founding MPM, Dr. Gadicke was at The Boston Consulting Group. He received an MD from J.W. Goethe University in Frankfurt and held research positions at the Whitehead Institute at MIT and the Biochemistry Department at Harvard University. At the German Cancer Research Center, he focused on HPV16 and 18 in Professor Harald zur Hausen's group (Nobel Laureate in Physiology or Medicine, 2008). Ansbert is a member of the Board of Fellows of Harvard Medical School and the Research Advisory Council of the Massachusetts General Hospital.


Patrick Baeuerle, PhD | MPM Capital, TCR2 Founder

Dr. Baeuerle is a Managing Director of MPM Capital and Founder of TCR2. Prior to joining MPM, he served as Vice President, Research, and General Manager at Amgen Research (Munich) GmbH where he pioneered the development of the BiTE technology and spearheaded the development of Blincyto®, a bispecific T cell-engaging antibody which received accelerated FDA approval for the treatment of relapsed/refractory ALL. He worked for the last 18 years on pharmaceutical strategies for engaging patient T cells for cancer therapy. From 1998-2012, Dr. Baeuerle served as Chief Scientific Officer for Micromet, and earlier oversaw drug discovery at Tularik. He also served as Professor and Chairman of Biochemistry and Molecular Biology at the Medical Faculty of Freiburg University, Germany, and conducted seminal research on transcription factor NF-kappaB. Dr. Baeuerle was rated Germany’s most frequently cited biomedical scientist of the decade (1990-1999), and among the top 50 worldwide (1990-1997), with more than 230 publications to date. He holds a PhD in biology from the University of Munich, and performed post-doctoral research with Dr. David Baltimore at the Whitehead Institute in Cambridge, MA. He is also an Honorary Professor of Immunology of the Medical Faculty at Munich University.


Mitchell (Mitch) Finer, PhD | MPM Capital, Oncorus

Dr. Finer is a Managing Director of MPM Capital and the Chief Executive Officer and Chief Scientific Officer of Oncorus Inc, focused on oncolytic herpes viruses for the treatment of GBM and other malignancies. For three decades, Dr. Finer has focused on utilizing novel platforms of cell and gene therapy, cancer immunotherapy and regenerative medicine to develop products from conception through phase III clinical studies. Prior to MPM, Dr. Finer served as Chief Scientific Officer of bluebird bio where he was responsible for strategic build of its gene-modified adult hematopoietic stem cell therapy business and led the strategic development and partnering of its CAR-T and genome engineering programs. Prior to bluebird bio, Dr. Finer served as CEO of Intracel Corporation and Genteric Inc, VP Research for Cell Genesys and the Gencell division of Aventis Pharma (now Sanofi) and SVP of Development at Novacell (now Viacyte). Dr. Finer also successfully co-founded Avalanche Biotechnologies (now Adverum Biotechnologies). Dr. Finer received his PhD in Biochemistry and Molecular Biology from Harvard University and completed a post-doctoral fellowship at the Whitehead Institute for Biomedical Research at MIT.


Morana Jovan-Embiricos, PhD | F2 Ventures

Dr. Jovan-Embiricos is the founder of F2 Ventures. She has extensive experience in both the public and private biotechnology equity markets through a series of funds launched at F2 since 2003. She also successfully managed a biotech allocation for one of the largest hedge funds in the USA. Prior to F2, Dr. Jovan-Embiricos was a Partner with MPM Capital working both on the investment side and directly with portfolio companies to help them attain critical business development milestones and securing appropriate exits either through trade sale or an IPO. She also led life sciences activities at Banque Syz & Co in Geneva, launching one of the first long only biotech funds in Switzerland. Dr. Jovan-Embiricos is also a member of the Board of Damon Runyon Cancer Research Foundation. She holds an Executive Business Program from Stanford-National University of Singapore and was a post-doctoral fellow at Harvard University having worked on protein un-caging in the Department of Developmental Biology. She received her PhD in Biophysical Chemistry from the University of Cambridge.


Garry Menzel, PhD and MBA | TCR2 Chief Executive Officer

Dr. Menzel joined TCR2 in 2016 as a Director and Chief Executive Officer. He has over 20 years of experience in building healthcare businesses and leading high-performing teams of professionals. He has also led multiple corporate transactions, including private financings, initial public offerings, licensing and M&A. Prior to TCR2, he was the Chief Strategy Officer at Axcella Health, the Chief Financial Officer at DaVita Healthcare (NYSE: DVA), and the Chief Operating Officer at Regulus Therapeutics (NASDAQ:RGLS). Dr. Menzel also had global leadership roles in running the biotechnology practices at Goldman Sachs and Credit Suisse. In addition, he was a consultant with Bain & Company. Dr. Menzel earned his PhD from the University of Cambridge for studying the regulation of oncogenes in immune cells. He also has a MBA from the Stanford Graduate School of Business.